PharmaJet and Scancell Team Up for Innovative Cancer Therapy
PharmaJet, an innovator in needle-free delivery technology based in Golden, Colorado, has entered into a significant agreement with Scancell Holdings plc. This collaboration is an important step toward developing and commercializing a cutting-edge DNA vaccine targeting melanoma, referred to as Immunobody® SCIB1/iSCIB1+. Their partnership underscores the critical role of effective treatment delivery while aiming to improve the overall experience for patients in oncology.
Details of the Agreement
This strategic partnership allows Scancell to utilize the PharmaJet Stratis® Intramuscular (IM) Needle-free System, which is well-regarded thanks to its FDA 510(k) clearance and CE mark. PharmaJet will benefit from various development milestones and will earn royalties on sales after the product is commercialized. Meanwhile, Scancell will handle the clinical and regulatory development, along with marketing the combined product.
Improving Vaccine Delivery and Effectiveness
PharmaJet's needle-free technology significantly enhances how the SCIB1/iSCIB1+ vaccine is absorbed by engaging the body’s immune cells more effectively. To date, a total of 171 doses have been administered safely to 60 patients across 15 clinical sites using the Stratis system. This partnership opens the door to an off-the-shelf therapeutic option, allowing for quicker access to viable cancer treatment, which greatly improves the patient experience.
A Vision for Future Cancer Treatments
Professor Lindy Durrant, the Chief Executive Officer of Scancell, expressed her optimism about the partnership, stating, "Securing long-term supply for the PharmaJet Stratis Needle-free Injection System is essential for the ongoing clinical and commercial development of iSCIB1+. Our aim has always been to offer a safe and effective therapy that generates robust immune responses for patients facing advanced melanoma. We believe this collaboration will genuinely make a difference in the lives of those affected by this challenging disease."
The Scientific Foundation of the Collaboration
Recent findings published in Vaccines Journal (MDPI) highlighted that using PharmaJet's needle-free technology for delivering DNA vaccines resulted in better tissue distribution and cellular uptake. This discovery emphasizes the potential of this partnership to enhance the effectiveness of vaccine formulations, signaling a notable advancement in cancer therapy delivery systems. Nathalie Landry, Chief Scientific Officer at PharmaJet, remarked, "The partnership with Scancell strengthens our position as leaders in delivering nucleic acid vaccines and immunotherapies. We are eager to collaborate with Scancell to further develop innovative strategies for improving outcomes for melanoma patients worldwide."
PharmaJet's Commitment and Mission
PharmaJet remains dedicated to improving the efficiency and accessibility of vaccinations through its Precision Delivery Systems™. The Stratis® System is known for its ability to deliver vaccines intramuscularly and has received several global certifications, ensuring its readiness for use across various immunization programs. The company’s broader mission is to significantly enhance public health by advancing injectable therapies.
About Scancell and Its Innovations
Scancell is a prominent clinical-stage biopharmaceutical company focused on developing groundbreaking treatments for unmet needs in cancer care. Through innovative platforms like Moditope® and ImmunoBody®, Scancell strives to establish a strong pipeline of cancer therapies. Their unique methodology boosts immune response mechanisms, which are crucial for effectively targeting and eliminating malignant cells. The partnership with PharmaJet represents a powerful fusion of expertise dedicated to transforming cancer treatment.
Frequently Asked Questions
What is the main goal of the partnership between PharmaJet and Scancell?
The partnership focuses on developing and commercializing a needle-free DNA vaccine for melanoma, aiming to improve treatment delivery and the overall patient experience.
How does PharmaJet's technology enhance the vaccine's effectiveness?
PharmaJet's needle-free delivery system enhances the uptake of the vaccine, ensuring a more efficient immune response while making the experience more comfortable for patients.
What roles do each company hold in this collaboration?
Scancell handles the clinical development and commercialization aspects, while PharmaJet will receive development payments and royalties from the product's sales.
What are the benefits of using needle-free delivery for vaccines?
Needle-free delivery improves tissue distribution, cellular uptake, and overall immunogenicity compared to traditional needle methods, which can lead to better vaccine efficacy.
What is the mission of PharmaJet?
PharmaJet aims to enhance the performance and outcomes of injectable therapies, striving to make a positive impact on public health through improved vaccine delivery systems.
